Cargando…
Decreased Th1-Type Inflammatory Cytokine Expression in the Skin Is Associated with Persisting Symptoms after Treatment of Erythema Migrans
BACKGROUND: Despite the good prognosis of erythema migrans (EM), some patients have persisting symptoms of various character and duration post-treatment. Several factors may affect the clinical outcome of EM, e.g. the early interaction between Borrelia (B.) burgdorferi and the host immune response,...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069060/ https://www.ncbi.nlm.nih.gov/pubmed/21483819 http://dx.doi.org/10.1371/journal.pone.0018220 |
_version_ | 1782201314490449920 |
---|---|
author | Sjöwall, Johanna Fryland, Linda Nordberg, Marika Sjögren, Florence Garpmo, Ulf Jansson, Christian Carlsson, Sten-Anders Bergström, Sven Ernerudh, Jan Nyman, Dag Forsberg, Pia Ekerfelt, Christina |
author_facet | Sjöwall, Johanna Fryland, Linda Nordberg, Marika Sjögren, Florence Garpmo, Ulf Jansson, Christian Carlsson, Sten-Anders Bergström, Sven Ernerudh, Jan Nyman, Dag Forsberg, Pia Ekerfelt, Christina |
author_sort | Sjöwall, Johanna |
collection | PubMed |
description | BACKGROUND: Despite the good prognosis of erythema migrans (EM), some patients have persisting symptoms of various character and duration post-treatment. Several factors may affect the clinical outcome of EM, e.g. the early interaction between Borrelia (B.) burgdorferi and the host immune response, the B. burgdorferi genotype, antibiotic treatment as well as other clinical circumstances. Our study was designed to determine whether early cytokine expression in the skin and in peripheral blood in patients with EM is associated with the clinical outcome. METHODS: A prospective follow-up study of 109 patients with EM was conducted at the Åland Islands, Finland. Symptoms were evaluated at 3, 6, 12 and 24 months post-treatment. Skin biopsies from the EM and healthy skin were immunohistochemically analysed for expression of interleukin (IL)-4, IL-10, IL-12p70 and interferon (IFN)-γ, as well as for B. burgdorferi DNA. Blood samples were analysed for B. burgdorferi antibodies, allergic predisposition and levels of systemic cytokines. FINDINGS: None of the patients developed late manifestations of Lyme borreliosis. However, at the 6-month follow-up, 7 of 88 patients reported persisting symptoms of diverse character. Compared to asymptomatic patients, these 7 patients showed decreased expression of the Th1-associated cytokine IFN-γ in the EM biopsies (p = 0.003). B. afzelii DNA was found in 48%, B. garinii in 15% and B. burgdorferi sensu stricto in 1% of the EM biopsies, and species distribution was the same in patients with and without post-treatment symptoms. The two groups did not differ regarding baseline patient characteristics, B. burgdorferi antibodies, allergic predisposition or systemic cytokine levels. CONCLUSION: Patients with persisting symptoms following an EM show a decreased Th1-type inflammatory response in infected skin early during the infection, which might reflect a dysregulation of the early immune response. This finding supports the importance of an early, local Th1-type response for optimal resolution of LB. |
format | Text |
id | pubmed-3069060 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30690602011-04-11 Decreased Th1-Type Inflammatory Cytokine Expression in the Skin Is Associated with Persisting Symptoms after Treatment of Erythema Migrans Sjöwall, Johanna Fryland, Linda Nordberg, Marika Sjögren, Florence Garpmo, Ulf Jansson, Christian Carlsson, Sten-Anders Bergström, Sven Ernerudh, Jan Nyman, Dag Forsberg, Pia Ekerfelt, Christina PLoS One Research Article BACKGROUND: Despite the good prognosis of erythema migrans (EM), some patients have persisting symptoms of various character and duration post-treatment. Several factors may affect the clinical outcome of EM, e.g. the early interaction between Borrelia (B.) burgdorferi and the host immune response, the B. burgdorferi genotype, antibiotic treatment as well as other clinical circumstances. Our study was designed to determine whether early cytokine expression in the skin and in peripheral blood in patients with EM is associated with the clinical outcome. METHODS: A prospective follow-up study of 109 patients with EM was conducted at the Åland Islands, Finland. Symptoms were evaluated at 3, 6, 12 and 24 months post-treatment. Skin biopsies from the EM and healthy skin were immunohistochemically analysed for expression of interleukin (IL)-4, IL-10, IL-12p70 and interferon (IFN)-γ, as well as for B. burgdorferi DNA. Blood samples were analysed for B. burgdorferi antibodies, allergic predisposition and levels of systemic cytokines. FINDINGS: None of the patients developed late manifestations of Lyme borreliosis. However, at the 6-month follow-up, 7 of 88 patients reported persisting symptoms of diverse character. Compared to asymptomatic patients, these 7 patients showed decreased expression of the Th1-associated cytokine IFN-γ in the EM biopsies (p = 0.003). B. afzelii DNA was found in 48%, B. garinii in 15% and B. burgdorferi sensu stricto in 1% of the EM biopsies, and species distribution was the same in patients with and without post-treatment symptoms. The two groups did not differ regarding baseline patient characteristics, B. burgdorferi antibodies, allergic predisposition or systemic cytokine levels. CONCLUSION: Patients with persisting symptoms following an EM show a decreased Th1-type inflammatory response in infected skin early during the infection, which might reflect a dysregulation of the early immune response. This finding supports the importance of an early, local Th1-type response for optimal resolution of LB. Public Library of Science 2011-03-31 /pmc/articles/PMC3069060/ /pubmed/21483819 http://dx.doi.org/10.1371/journal.pone.0018220 Text en Sjöwall et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Sjöwall, Johanna Fryland, Linda Nordberg, Marika Sjögren, Florence Garpmo, Ulf Jansson, Christian Carlsson, Sten-Anders Bergström, Sven Ernerudh, Jan Nyman, Dag Forsberg, Pia Ekerfelt, Christina Decreased Th1-Type Inflammatory Cytokine Expression in the Skin Is Associated with Persisting Symptoms after Treatment of Erythema Migrans |
title | Decreased Th1-Type Inflammatory Cytokine Expression in the Skin Is Associated with Persisting Symptoms after Treatment of Erythema Migrans |
title_full | Decreased Th1-Type Inflammatory Cytokine Expression in the Skin Is Associated with Persisting Symptoms after Treatment of Erythema Migrans |
title_fullStr | Decreased Th1-Type Inflammatory Cytokine Expression in the Skin Is Associated with Persisting Symptoms after Treatment of Erythema Migrans |
title_full_unstemmed | Decreased Th1-Type Inflammatory Cytokine Expression in the Skin Is Associated with Persisting Symptoms after Treatment of Erythema Migrans |
title_short | Decreased Th1-Type Inflammatory Cytokine Expression in the Skin Is Associated with Persisting Symptoms after Treatment of Erythema Migrans |
title_sort | decreased th1-type inflammatory cytokine expression in the skin is associated with persisting symptoms after treatment of erythema migrans |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069060/ https://www.ncbi.nlm.nih.gov/pubmed/21483819 http://dx.doi.org/10.1371/journal.pone.0018220 |
work_keys_str_mv | AT sjowalljohanna decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans AT frylandlinda decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans AT nordbergmarika decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans AT sjogrenflorence decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans AT garpmoulf decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans AT janssonchristian decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans AT carlssonstenanders decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans AT bergstromsven decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans AT ernerudhjan decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans AT nymandag decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans AT forsbergpia decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans AT ekerfeltchristina decreasedth1typeinflammatorycytokineexpressionintheskinisassociatedwithpersistingsymptomsaftertreatmentoferythemamigrans |